CEO
1nhaler
1nhaler has developed a breath-activated, single-dose dry powder inhaler made primarily from FSC-certified cardboard, weighing just 2 grams. The propellant-free, electronics-free device is designed to be ultra-portable, low-cost, and environmentally friendly, with performance data showing comparability to the market-leading salbutamol product for lung deposition. The platform technology extends beyond respiratory conditions to potential applications in epilepsy, allergies, Parkinson's, rescue medications, anti-infectives, and vaccines.
- Medical Devices
- Healthcare Technology
- Clean Technology
- Hardware
- Biotechnology
Updated yesterday
Funding
Raised to date
£9.2MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $11.7Macross 5 rounds
ABISE
£2.2M · Seed Follow-On
Announced Nov 2026 · from article date
Disclosed cumulative: $11.7M
5/5
RoundDateAmountValuationInvestors
Founders
Product
Problem
Traditional inhaler devices are bulky, costly, difficult to use, and environmentally harmful due to plastic waste. Many medications that could benefit from inhalable delivery—including rescue medications, anti-infectives, and vaccines—lack a simple, low-cost, self-administered option, and clinical trials are limited to bulky plastic capsule inhalers.
Solution
1nhaler provides a breath-activated, single-dose dry powder inhaler constructed primarily from FSC-certified cardboard. The device is ultra-portable, weighing just 2 grams, and is designed to be easy to use, low cost, and environmentally friendly. It is propellant-free and electronics-free, leveraging advancements in dry powder formulations to minimize API wastage. The company’s lead project uses salbutamol for asthma relief, with current performance data showing comparability with the market-leading product for drug deposition to the lungs. The patented pop-up cardboard technology is positioned as a platform applicable beyond respiratory conditions, including epilepsy, allergies, Parkinson’s, rescue medications, anti-infectives, and vaccines.
Target Audience
Primary customers are pharmaceutical companies and clinical trial sponsors seeking a low-cost, portable, single-dose inhaler platform for respiratory and non-respiratory inhaled medications, as well as patients and prescribers needing acute and relatively rare-use inhalers for conditions like asthma, anaphylaxis, and migraine.
Features
- Breath-activated, single-dose design that eliminates drug agglomeration and ensures reliable dosing
- ~90% cardboard construction using FSC-certified card, weighing just 2g per unit
- Propellant-free and electronics-free, minimizing environmental impact and plastic waste
- Patented pop-up cardboard technology that is portable and easy to use without complex instructions
- Performance data demonstrating comparability with the market-leading salbutamol product for lung deposition
- Platform technology applicable beyond respiratory conditions, including epilepsy, allergies, Parkinson’s, rescue medications, anti-infectives, and vaccines